DE69838417D1 - An caml bindender lymphozyteoberflächenrezeptor, nukleinsäuren die dafür kodieren und verfahren zur verwendung - Google Patents
An caml bindender lymphozyteoberflächenrezeptor, nukleinsäuren die dafür kodieren und verfahren zur verwendungInfo
- Publication number
- DE69838417D1 DE69838417D1 DE69838417T DE69838417T DE69838417D1 DE 69838417 D1 DE69838417 D1 DE 69838417D1 DE 69838417 T DE69838417 T DE 69838417T DE 69838417 T DE69838417 T DE 69838417T DE 69838417 D1 DE69838417 D1 DE 69838417D1
- Authority
- DE
- Germany
- Prior art keywords
- caml
- nucleic acids
- surface receptor
- lymphocyte surface
- acids coded
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/82—Proteins from microorganisms
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/810,572 US5969102A (en) | 1997-03-03 | 1997-03-03 | Lymphocyte surface receptor that binds CAML, nucleic acids encoding the same and methods of use thereof |
US810572 | 1997-03-03 | ||
PCT/US1998/004270 WO1998039361A1 (en) | 1997-03-03 | 1998-03-03 | A lymphocyte surface receptor that binds caml, nucleic acids encoding the same and methods of use thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69838417D1 true DE69838417D1 (de) | 2007-10-25 |
DE69838417T2 DE69838417T2 (de) | 2008-05-29 |
Family
ID=25204137
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69838417T Expired - Lifetime DE69838417T2 (de) | 1997-03-03 | 1998-03-03 | An caml bindender lymphozyteoberflächenrezeptor, nukleinsäuren die dafür kodieren und verfahren zur verwendung |
Country Status (11)
Country | Link |
---|---|
US (7) | US5969102A (de) |
EP (3) | EP2292654A3 (de) |
JP (1) | JP3594975B2 (de) |
AT (1) | ATE373012T1 (de) |
AU (1) | AU732119B2 (de) |
CA (1) | CA2284078C (de) |
DE (1) | DE69838417T2 (de) |
DK (1) | DK0964874T3 (de) |
ES (2) | ES2552095T3 (de) |
PT (1) | PT964874E (de) |
WO (1) | WO1998039361A1 (de) |
Families Citing this family (80)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA95960B (en) * | 1994-03-14 | 1995-10-10 | Genetics Inst | Use of interleukin-12 antagonists in the treatment of autoimmune diseases |
US6830751B1 (en) | 1994-03-14 | 2004-12-14 | Genetics Institute, Llc | Use of IL-12 antagonists in the treatment of rheumatoid arthritis |
US8212004B2 (en) * | 1999-03-02 | 2012-07-03 | Human Genome Sciences, Inc. | Neutrokine-alpha fusion proteins |
US6812327B1 (en) | 1996-10-25 | 2004-11-02 | Human Genome Sciences, Inc. | Neutrokine-alpha polypeptides |
US5969102A (en) * | 1997-03-03 | 1999-10-19 | St. Jude Children's Research Hospital | Lymphocyte surface receptor that binds CAML, nucleic acids encoding the same and methods of use thereof |
US7488590B2 (en) | 1998-10-23 | 2009-02-10 | Amgen Inc. | Modified peptides as therapeutic agents |
GB9828628D0 (en) | 1998-12-23 | 1999-02-17 | Glaxo Group Ltd | Novel ligand |
AU2005200008B2 (en) * | 1999-01-07 | 2008-03-06 | Zymogenetics, Inc. | Soluble receptor BR43x2 and methods of using |
US7833529B1 (en) | 1999-01-07 | 2010-11-16 | Zymogenetics, Inc. | Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor |
SI1642972T1 (sl) * | 1999-01-07 | 2010-05-31 | Zymogenetics Inc | Terapevtske uporabe BR X topnih receptorjev |
US20060067933A1 (en) * | 1999-01-07 | 2006-03-30 | Gross Jane A | Soluble receptor BR43x2 and methods of using |
DK1415659T3 (da) * | 1999-01-25 | 2011-10-03 | Biogen Idec Inc | BAFF, inhibitorer og anvendelse deraf i modulering af B-cellerespons |
US20050100548A1 (en) * | 2001-07-24 | 2005-05-12 | Biogen Idec Ma Inc. | BAFF, inhibitors thereof and their use in the modulation of B-cell response |
US20030095967A1 (en) * | 1999-01-25 | 2003-05-22 | Mackay Fabienne | BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders |
AU3633000A (en) * | 1999-03-26 | 2000-10-16 | Human Genome Sciences, Inc. | Neutrokine-alpha binding proteins and methods based thereon |
US20030022233A1 (en) * | 1999-04-30 | 2003-01-30 | Raymond G. Goodwin | Methods of use of the taci/taci-l interaction |
ATE360693T1 (de) * | 1999-08-17 | 2007-05-15 | Biogen Idec Inc | Baff rezeptor (bcma), ein immunoregulatorisches mittel |
UA74798C2 (uk) * | 1999-10-06 | 2006-02-15 | Байоджен Айдек Ма Інк. | Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами |
US20020160416A1 (en) * | 2000-02-11 | 2002-10-31 | Boyle William J. | Receptor from TNF family |
DK1255558T3 (da) | 2000-02-16 | 2006-10-23 | Genentech Inc | Anti-april antistoffer og hybridomaceller |
US6969519B2 (en) * | 2000-03-10 | 2005-11-29 | Human Genome Sciences, Inc. | Methods of using an agonistic antibody human tumor necrosis factor receptor (TR17) |
BR0110610A (pt) | 2000-04-11 | 2003-04-29 | Genentech Inc | Anticorpos isolados, imunoconjugados, cadeias de polipeptìdeos, ácido nucléico isolado, vetor, célula hospedeira, processo de produção de anticorpo ou cadeia de polipeptìdeos, método de tratamento de disfunções em mamìferos, método de indução da apoptose de uma célula cancerosa, método para matar uma célula b, método para matar uma célula que expresse um receptor de erbb e usos dos anticorpos isolados |
NZ521629A (en) * | 2000-04-27 | 2004-05-28 | Biogen Inc | TACI as an anti-tumor agent |
EP1746106A3 (de) * | 2000-04-27 | 2007-03-14 | Biogen Idec MA Inc. | Verwendung von TACI als Antitumormittel |
US20040013674A1 (en) * | 2001-04-27 | 2004-01-22 | Christine Ambrose | Taci as an anti-tumor agent |
US6774106B2 (en) | 2000-05-12 | 2004-08-10 | Amgen Inc. | Methods and compositions of matter concerning APRIL/G70, BCMA, BLYS/AGP-3 and TACI |
EP1294949A4 (de) * | 2000-06-15 | 2004-08-25 | Human Genome Sciences Inc | Menschlicher tumornekrosefaktor delta und epsilon |
ATE494304T1 (de) | 2000-06-16 | 2011-01-15 | Human Genome Sciences Inc | Immunspezifisch bindende antikörper gegen blys |
US7879328B2 (en) * | 2000-06-16 | 2011-02-01 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to B lymphocyte stimulator |
IL153651A0 (en) * | 2000-07-07 | 2003-07-06 | Eisai Co Ltd | Fungal cell wall synthesis gene |
CA2415473A1 (en) | 2000-07-27 | 2002-02-07 | Genentech, Inc. | Apo-2l receptor agonist and cpt-11 synergism |
US20030091565A1 (en) | 2000-08-18 | 2003-05-15 | Beltzer James P. | Binding polypeptides and methods based thereon |
UA83458C2 (uk) * | 2000-09-18 | 2008-07-25 | Байоджен Айдек Ма Інк. | Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf) |
WO2002046231A2 (en) * | 2000-12-07 | 2002-06-13 | The University Of British Columbia | Caml-binding peptides |
WO2002066516A2 (en) * | 2001-02-20 | 2002-08-29 | Zymogenetics, Inc. | Antibodies that bind both bcma and taci |
CN1970077A (zh) | 2001-05-11 | 2007-05-30 | 安姆根有限公司 | 与tall-1结合的肽和相关分子 |
CA2448123C (en) * | 2001-05-24 | 2012-09-11 | Zymogenetics, Inc. | Taci-immunoglobulin fusion proteins |
DE60235989D1 (de) | 2001-06-26 | 2010-05-27 | Amgen Fremont Inc | Antikörper gegen opgl |
DE10131922A1 (de) * | 2001-07-02 | 2003-01-30 | Brahms Ag | Verwendung des Calcineurin B Homologen Proteins (CHP) für die Diagnose und Therapie von Entzündungserkrankungen und Sepsis |
EP1409544B1 (de) | 2001-07-03 | 2009-06-17 | Genentech, Inc. | Humane dr4-antikörper und deren anwendungen |
US7604989B2 (en) * | 2001-07-10 | 2009-10-20 | Johns Hopkins University | Inhibition of apoptosis process and improvement of cell performance |
KR20040019105A (ko) * | 2001-08-03 | 2004-03-04 | 제넨테크, 인크. | TACIs 및 BR3 폴리펩티드 및 이의 용도 |
US6551615B1 (en) * | 2001-10-18 | 2003-04-22 | M/S. Strides Arcolab Limited | Dexibuprofen-containing soft gelatin capsules and process for preparing the same |
WO2003072713A2 (en) * | 2002-02-21 | 2003-09-04 | Biogen Idec Ma Inc. | Use of bcma as an immunoregulatory agent |
US20040038303A1 (en) * | 2002-04-08 | 2004-02-26 | Unger Gretchen M. | Biologic modulations with nanoparticles |
US8025873B2 (en) * | 2002-06-20 | 2011-09-27 | Paladin Labs, Inc. | Chimeric antigens for eliciting an immune response |
US6890725B2 (en) * | 2002-07-23 | 2005-05-10 | Rigel Pharmaceuticals, Inc. | Modulators of B-lymphocyte activation, myosin-1F compositions and methods of use |
MXPA05000940A (es) * | 2002-07-25 | 2005-05-16 | Genentech Inc | Anticuerpos taci y su uso. |
DE60329116D1 (de) | 2002-10-11 | 2009-10-15 | Zymogenetics Inc | Herstellung von homotrimeren fusionsproteinen |
WO2004094620A2 (en) | 2003-03-28 | 2004-11-04 | Biogen Idec Ma Inc. | Truncated baff receptors |
US20050163775A1 (en) * | 2003-06-05 | 2005-07-28 | Genentech, Inc. | Combination therapy for B cell disorders |
WO2005005462A2 (en) * | 2003-06-05 | 2005-01-20 | Genentech, Inc. | Blys antagonists and uses thereof |
US7211407B2 (en) * | 2003-07-15 | 2007-05-01 | Chan Test, Inc. | High throughput assay systems and methods for identifying agents that alter surface expression of integral membrane proteins |
WO2005075511A1 (en) * | 2004-01-29 | 2005-08-18 | Genentech, Inc. | Variants of the extracellular domain of bcma and uses thereof |
WO2005087810A2 (en) | 2004-03-08 | 2005-09-22 | Zymogenetics, Inc. | Dimeric fusion proteins and materials and methods for producing them |
EP1812472A1 (de) * | 2004-11-04 | 2007-08-01 | Genentech, Inc. | An baff und/oder april bindende polypeptide |
CA2596276A1 (en) * | 2005-01-28 | 2006-08-03 | Biogen Idec Ma Inc. | Use of baff to treat th2-mediated conditions |
US8808696B2 (en) * | 2005-08-09 | 2014-08-19 | Ares Trading S.A. | Methods for the treatment and prevention of abnormal cell proliferation using TACI-fusion molecules |
EA016083B1 (ru) * | 2005-08-09 | 2012-02-28 | Займоджинетикс, Инк. | СПОСОБ ЛЕЧЕНИЯ НЕХОДЖКИНСКОЙ ЛИМФОМЫ С ПОМОЩЬЮ СЛИТОЙ МОЛЕКУЛЫ TACI-Ig |
NZ568204A (en) * | 2005-10-13 | 2012-01-12 | Human Genome Sciences Inc | Methods and compositions for use in treatment of patients with autoantibody positive diseases |
US9168286B2 (en) * | 2005-10-13 | 2015-10-27 | Human Genome Sciences, Inc. | Methods and compositions for use in treatment of patients with autoantibody positive disease |
PE20070684A1 (es) | 2005-11-14 | 2007-08-06 | Amgen Inc | MOLECULAS QUIMERICAS DE ANTICUERPO RANKL-PTH/PTHrP |
ES2618543T3 (es) * | 2005-11-23 | 2017-06-21 | Genentech, Inc. | Métodos y composiciones relacionados con ensayos de linfocitos B |
WO2007123765A2 (en) | 2006-03-31 | 2007-11-01 | Human Genome Sciences Inc. | Neutrokine-alpha and neutrokine-alpha splice variant |
CN101489573B (zh) * | 2006-05-15 | 2013-05-22 | 阿雷斯贸易股份有限公司 | 用TACI-Ig融合分子治疗自身免疫疾病的方法 |
UA99262C2 (uk) | 2006-08-28 | 2012-08-10 | Арес Трейдінг С.А. | СПОСІБ ЗМЕНШЕННЯ КОНЦЕНТРАЦІЇ ВІЛЬНИХ Fc-ЧАСТИН В РІДИНІ, ЩО МІСТИТЬ Fc-ВМІСНИЙ БІЛОК |
UA99263C2 (ru) * | 2006-08-28 | 2012-08-10 | Арес Трейдинг С.А. | СПОСОБ ОЧИСТКИ Fc-СЛИТОГО БЕЛКА |
US20100063257A1 (en) | 2007-01-26 | 2010-03-11 | Merck Serono Sa | Purification of FC-TACI Fusion Proteins Using the Oilbody Technology |
HUE030134T2 (en) | 2007-10-16 | 2017-04-28 | Zymogenetics Inc | Combination of transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI) and anti-CD20 agents for the treatment of autoimmune diseases |
WO2010093993A2 (en) * | 2009-02-12 | 2010-08-19 | Human Genome Sciences, Inc. | Use of b lymphocyte stimulator protein antagonists to promote transplantation tolerance |
WO2011109280A1 (en) | 2010-03-05 | 2011-09-09 | Lerner Research Institute | Methods and compositions to treat immune-mediated disorders |
US9458246B2 (en) | 2013-03-13 | 2016-10-04 | Amgen Inc. | Proteins specific for BAFF and B7RP1 |
JOP20140087B1 (ar) | 2013-03-13 | 2021-08-17 | Amgen Inc | بروتينات مخصصة ل baff و b7rp1 وإستخداماتها |
CN110612119A (zh) | 2017-02-07 | 2019-12-24 | 西雅图儿童医院(Dba西雅图儿童研究所) | 磷脂醚(ple)car t细胞肿瘤靶向(ctct)剂 |
US11850262B2 (en) | 2017-02-28 | 2023-12-26 | Purdue Research Foundation | Compositions and methods for CAR T cell therapy |
AU2019209428A1 (en) | 2018-01-22 | 2020-07-30 | Endocyte, Inc. | Methods of use for CAR T cells |
KR20230029621A (ko) | 2020-05-08 | 2023-03-03 | 알파인 이뮨 사이언시즈, 인코포레이티드 | T 세포 억제 단백질을 포함하거나 포함하지 않는 april 및 baff 억제 면역조절 단백질 및 이의 사용 방법 |
EP4265269A1 (de) * | 2020-12-16 | 2023-10-25 | Good T Cells, Inc. | Verwendung von taci protein |
CN116867507A (zh) | 2021-08-10 | 2023-10-10 | 荣昌生物制药(烟台)股份有限公司 | 用TACI-Fc融合蛋白治疗IgA肾病的方法 |
EP4296287A1 (de) | 2021-09-30 | 2023-12-27 | RemeGen Co., Ltd. | Verfahren zur behandlung des sjögren-syndroms mit taci-fc-fusionsprotein |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
NL7807532A (nl) | 1978-07-13 | 1980-01-15 | Akzo Nv | Metaal-immunotest. |
NL8000173A (nl) | 1980-01-11 | 1981-08-03 | Akzo Nv | Toepassing van in water dispergeerbare, hydrofobe kleurstoffen als label in immunochemische testen. |
US4650764A (en) | 1983-04-12 | 1987-03-17 | Wisconsin Alumni Research Foundation | Helper cell |
US4703017C1 (en) | 1984-02-14 | 2001-12-04 | Becton Dickinson Co | Solid phase assay with visual readout |
US4751181A (en) * | 1984-12-31 | 1988-06-14 | Duke University | Methods and compositions useful in the diagnosis and treatment of autoimmune diseases |
US4631211A (en) | 1985-03-25 | 1986-12-23 | Scripps Clinic & Research Foundation | Means for sequential solid phase organic synthesis and methods using the same |
CA1338860C (en) | 1987-04-13 | 1997-01-21 | Peter Parker | Radiolabelling of proteins |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
DE3882058T2 (de) | 1987-02-27 | 1994-01-13 | Eastman Kodak Co | Immunoreaktives Reagens, Verfahren zu seiner Herstellung und seine Verwendung zur Bestimmung einer immunoreaktiven Spezies. |
EP0280559B1 (de) | 1987-02-27 | 1993-10-20 | EASTMAN KODAK COMPANY (a New Jersey corporation) | Agglutinationsimmunotest und Satz zur Bestimmung einer mehrwertigen Immunspezies unter Verwendung einer gepufferten Salzwasch-Lösung |
US4857453A (en) | 1987-04-07 | 1989-08-15 | Syntex (U.S.A.) Inc. | Immunoassay device |
US4980289A (en) | 1987-04-27 | 1990-12-25 | Wisconsin Alumni Research Foundation | Promoter deficient retroviral vector |
DE3856542T2 (de) | 1987-04-27 | 2003-10-30 | Inverness Medical Switzerland | Testgerät zur Durchführung von spezifischen Bindungsprüfungen |
US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
DE3856559T2 (de) | 1987-05-21 | 2004-04-29 | Micromet Ag | Multifunktionelle Proteine mit vorbestimmter Zielsetzung |
US5010175A (en) | 1988-05-02 | 1991-04-23 | The Regents Of The University Of California | General method for producing and selecting peptides with specific properties |
IL92124A (en) | 1988-10-28 | 1996-10-31 | Sidney Pestka | Recombinant proteins modified to contain post-phosphorylation that do not occur in nature |
US5124263A (en) | 1989-01-12 | 1992-06-23 | Wisconsin Alumni Research Foundation | Recombination resistant retroviral helper cell and products produced thereby |
US5354844A (en) | 1989-03-16 | 1994-10-11 | Boehringer Ingelheim International Gmbh | Protein-polycation conjugates |
US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
US5139749A (en) | 1990-06-22 | 1992-08-18 | Tas, Inc. | Fluidized calcining process |
CA2074825C (en) | 1990-12-14 | 2005-04-12 | Daniel J. Capon | Chimeric chains for receptor-associated signal transduction pathways |
CA2103577A1 (en) | 1991-02-07 | 1992-08-08 | Michael Kahn | Conformationally restricted mimetics of beta turns and beta bulges and peptides containing the same |
ATE366741T1 (de) | 1993-05-27 | 2007-08-15 | Aventis Pharma Inc | Topologisch getrennte, kodierende festphasen- bibliotheken |
WO1995007358A1 (en) | 1993-07-30 | 1995-03-16 | University Of Medicine & Dentistry Of New Jersey | Efficient gene transfer into primary lymphocytes |
US5650550A (en) * | 1993-10-01 | 1997-07-22 | The United States Of America As Represented By The Department Of Health And Human Services | Mutant mice having a deficit of functional estrogen receptors |
WO1995028494A1 (en) | 1994-04-15 | 1995-10-26 | Targeted Genetics Corporation | Gene delivery fusion proteins |
US5523227A (en) * | 1994-06-17 | 1996-06-04 | The Board Of Trustees Of The Leland Stanford Junior Univ. | DNA encoding calcium-signal modulating cyclophilin ligand |
EP0871645B1 (de) * | 1994-12-15 | 2007-10-31 | Yeda Research And Development Co., Ltd. | Modulatoren der funktion des fas/ap01 rezeptors |
US5837544A (en) | 1995-02-02 | 1998-11-17 | Cell Genesys, Inc. | Method of inducing a cell to proliferate using a chimeric receptor comprising janus kinase |
US5712149A (en) | 1995-02-03 | 1998-01-27 | Cell Genesys, Inc. | Chimeric receptor molecules for delivery of co-stimulatory signals |
US6103521A (en) | 1995-02-06 | 2000-08-15 | Cell Genesys, Inc. | Multispecific chimeric receptors |
US5969102A (en) * | 1997-03-03 | 1999-10-19 | St. Jude Children's Research Hospital | Lymphocyte surface receptor that binds CAML, nucleic acids encoding the same and methods of use thereof |
US6685728B2 (en) * | 2002-01-25 | 2004-02-03 | Stryker Endoscopy | Threaded suture anchor and method of use |
US9002545B2 (en) | 2011-01-07 | 2015-04-07 | Wabtec Holding Corp. | Data improvement system and method |
-
1997
- 1997-03-03 US US08/810,572 patent/US5969102A/en not_active Expired - Lifetime
-
1998
- 1998-03-03 JP JP53877898A patent/JP3594975B2/ja not_active Expired - Lifetime
- 1998-03-03 ES ES05020384.3T patent/ES2552095T3/es not_active Expired - Lifetime
- 1998-03-03 DE DE69838417T patent/DE69838417T2/de not_active Expired - Lifetime
- 1998-03-03 PT PT98908948T patent/PT964874E/pt unknown
- 1998-03-03 AT AT98908948T patent/ATE373012T1/de active
- 1998-03-03 EP EP10179571A patent/EP2292654A3/de not_active Withdrawn
- 1998-03-03 EP EP98908948A patent/EP0964874B1/de not_active Expired - Lifetime
- 1998-03-03 ES ES98908948T patent/ES2292201T3/es not_active Expired - Lifetime
- 1998-03-03 CA CA2284078A patent/CA2284078C/en not_active Expired - Lifetime
- 1998-03-03 EP EP05020384.3A patent/EP1632500B1/de not_active Expired - Lifetime
- 1998-03-03 DK DK98908948T patent/DK0964874T3/da active
- 1998-03-03 AU AU66854/98A patent/AU732119B2/en not_active Expired
- 1998-03-03 WO PCT/US1998/004270 patent/WO1998039361A1/en active IP Right Grant
-
1999
- 1999-04-12 US US09/290,333 patent/US6316222B1/en not_active Expired - Lifetime
-
2001
- 2001-02-14 US US09/782,857 patent/US6500428B1/en not_active Expired - Lifetime
-
2002
- 2002-11-12 US US10/293,816 patent/US20030082173A1/en not_active Abandoned
-
2005
- 2005-03-14 US US11/079,418 patent/US20050183148A1/en not_active Abandoned
- 2005-12-23 US US11/318,156 patent/US7355005B2/en not_active Expired - Fee Related
-
2008
- 2008-02-07 US US12/027,720 patent/US20090226473A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JP3594975B2 (ja) | 2004-12-02 |
AU6685498A (en) | 1998-09-22 |
US6500428B1 (en) | 2002-12-31 |
EP2292654A2 (de) | 2011-03-09 |
CA2284078C (en) | 2014-09-09 |
WO1998039361A1 (en) | 1998-09-11 |
JP2001518080A (ja) | 2001-10-09 |
US6316222B1 (en) | 2001-11-13 |
EP0964874A1 (de) | 1999-12-22 |
DE69838417T2 (de) | 2008-05-29 |
AU732119B2 (en) | 2001-04-12 |
US20050183148A1 (en) | 2005-08-18 |
EP1632500B1 (de) | 2015-08-05 |
EP1632500A3 (de) | 2007-05-30 |
ATE373012T1 (de) | 2007-09-15 |
US7355005B2 (en) | 2008-04-08 |
EP0964874B1 (de) | 2007-09-12 |
ES2552095T3 (es) | 2015-11-25 |
DK0964874T3 (da) | 2007-12-10 |
US5969102A (en) | 1999-10-19 |
US20090226473A1 (en) | 2009-09-10 |
CA2284078A1 (en) | 1998-09-11 |
EP1632500A2 (de) | 2006-03-08 |
EP2292654A3 (de) | 2012-07-25 |
US20030082173A1 (en) | 2003-05-01 |
US20060101529A1 (en) | 2006-05-11 |
PT964874E (pt) | 2007-12-21 |
ES2292201T3 (es) | 2008-03-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69838417D1 (de) | An caml bindender lymphozyteoberflächenrezeptor, nukleinsäuren die dafür kodieren und verfahren zur verwendung | |
DE60042617D1 (de) | Verfahren zur therapeutischen Verwendung von löslichen rezeptoren BR43X2 | |
DE69508236D1 (de) | Verfahren zur herstellung von fluorierten olefinen und fluorkohlenwasserstoffen unter verwendung von fluoriertem olefin | |
DE69635076D1 (de) | Verfahren zur kontrollierung der sialylierung von durch säugetierzellkulturhergestellten protein | |
ATE195927T1 (de) | Verfahren zur oligomerisierung von olefinen | |
DE69824693D1 (de) | Ruthenium-Metathesekatalysator und Verfahren zur Olefinmetathese unter Verwendung des Katalysators | |
FI961251A0 (fi) | Ihmisten metabotrooppiset glutamaattireseptorialatyypit(HMR4, HMR6, HMR7)ja niihin liittyvät DNA-yhdisteet | |
DE69835154D1 (de) | Verfahren zur Bestimmung von Analyten mittels Antigenen, die in Thermoplasten eingebettet sind | |
DE69723860D1 (de) | VERFAHREN ZUR BESTIMMUNG VON IgE | |
ATE217636T1 (de) | Verfahren zur gewinnung von insulinvorläufern mit korrekt verbundenen cystinbrücken | |
DE69518550D1 (de) | Verfahren zur bereitung von kohlenwasserstoffe | |
DE60335216D1 (de) | Adiponektin-rezeptor und dafür kodierendes gen | |
ZA200409776B (en) | Immunoadhesin comprising a glycoprotein VI domain | |
DE69000163T2 (de) | Verfahren zur gewinnung von fluessigen kohlenwasserstoffen und einrichtung zur ausfuehrung dieses verfahrens. | |
DE69602534T2 (de) | Verfahren zur verwendung von metallocenkatalysatoren | |
DE69822629D1 (de) | Verfahren zur gerüstisomerisierung von olefinen | |
DE69830556D1 (de) | Verfahren zur Bestimmung von glykosylierten Proteinen | |
ATE341633T1 (de) | Verfahren zur spaltung von fusionproteinen | |
DE69703110T2 (de) | Verfahren zur vorschwefelung von kohlenwasserstoffumwandlungskatalysatoren | |
ATE156118T1 (de) | Verfahren zur herstellung von fibrinogen-rezeptor-antagonisten | |
DE69808040T2 (de) | Abwechselndes Verfahren zur Metathese von Olefinen | |
DE59505524D1 (de) | Verfahren zur carbonylierung von olefinen | |
ATE462721T1 (de) | Breit einsetzbares verfahren zur identifizierung von modulatoren von g-protein gekoppelten rezeptoren | |
DE69807148T2 (de) | Verfahren zur Hydroformylierung von Olefininen | |
WO2000011204A3 (en) | Homer interacting proteins |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |